A simple quantitative method for evaluation of angiogenesis activity

Assay and Drug Development Technologies

Volumn 2, Issue 1, 2004, Pages 31-38

  Wang, Hsin Sheng ^a   Hwang, Ling Ling ^b   Sue, Hsin Fang ^a,b   Lee, Kuo Min ^a   Chen, Chiung Tong ^a  

^a National Research Institutes   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; PACLITAXEL; SEMAXANIB; SURAMIN; CD31 ANTIGEN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANALYTIC METHOD; ANGIOGENESIS; ANIMAL TISSUE; AORTA; ARTICLE; CELL CULTURE; CELL GROWTH; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; IC 50; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NONHUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; ALGORITHM; ANIMAL; BIOSYNTHESIS; CYTOLOGY; DRUG EFFECT; DRUG SCREENING; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMAGE PROCESSING; ORGAN CULTURE TECHNIQUE; THORACIC AORTA; VASCULAR ENDOTHELIUM;

ALGORITHMS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; AORTA, THORACIC; COLORIMETRY; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; ORGAN CULTURE TECHNIQUES; RATS; TETRAZOLIUM SALTS; THIAZOLES;

EID: 2342518823     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/154065804322966298     Document Type: Article

References (35)

1. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763.
2. Battegay EJ: Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-346.
3. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 2001;28:536-542.
4. Nelson MA, Passeri J, Frishman WH: Therapeutic angiogenesis: a new treatment modality for ischemic heart disease. Heart Dis 2000;2:314-325.
5. Ausprunk DH, Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977;14: 53-65.
6. Nguyen M, Shing Y, Folkman J: Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 1994;47:31-40.
7. Nikiforidis G, Papazafiropoulos D, Siablis D, Karnabatidis D, Hatjikondi O, Dimopoulos J: Quantitative assessment of angiogenesis in the chick embryo and its chorioallantoic membrane by computerised analysis of angiographic images. Eur J Radiol 1999;29:168-179.
8. Jain RK, Schlenger K, Hockel M, Yuan F: Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203-1208.
9. Auerbach R, Akhtar N, Lewis RL, Shinners BL: Angiogenesis assays: problems and pitfalls. Cancer Metastasis Rev 2000;19:167-172.
10. Montesano R, Orci L, Vassalli P: In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983;97:1648-1652.
11. Zhu WH, Guo X, Villaschi S, Nicosia RF: Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab Invest 2000;80:545-555.
12. Burbridge MF, West DC: Rat aorta ring, 3D model of angiogenesis in vitro. In: Angiogenesis Protocols. Murray JC (ed.), pp. 185-204. Humana, Totowa, NJ, 2001.
13. Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD: Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway. J Pharmacol Exp Ther 2000; 292:31-37.
14. Nicosia RF, Ottinetti A: Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990;63:115-122.
15. Chen CT, Dun SL, Kwok EH, Dun NJ, Chang JK: Orexin A-like immunoreactivity in the rat brain. Neurosci Lett 1999;260:161-164.
16. Cory AH, Owen TC, Barltrop JA, Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-212.
17. 3H]thymidine incorporation with MTT- and MTS-based bioassays for human and murine IL-2 and IL-4 analysis. Tetrazolium assays provide markedly enhanced sensitivity. J Immunol Methods 1995;187:85-93.
18. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LM, Cherrington JM: Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
19. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, Engelhard H, Perricone M, Eidsvoog K, Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994;54:2654-2660.
20. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L: The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-239.
21. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-1849.
22. Chen CT, Gan Y, Au JLS, Wientjes MG: Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 1998; 58:2777-2783.
23. Venitz J: Pharmacokinetic-pharmacodynamic modeling of reversible drug effects. In: Handbook of Pharmacokinetic/Pharmacodynamic Correlation. Derendorf H, Hochhaus G (eds.), pp. 1-34. CRC Press, Boca Raton, FL, 1995.
24. 2. J Biol Chem 1999;274: 35562-35570.
25. Merwin JR, Newman W, Beall LD, Tucker A, Madri J: Vascular cells respond differentially to transforming growth factors beta 1 and beta 2 in vitro. Am J Pathol 1991; 138:37-51.
26. Au JLS, Li D, Gan Y, Gao X, Johnson AL, Johnston J, Millenbaugh NJ, Jang SH, Kuh HJ, Chen CT, Wientjes MG: Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. Cancer Res 1998;58:2141-2148.
27. Hosang M: Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-273.
28. Coffey RJ Jr, Leof EB, Shipley GD, Moses HL: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 1987;132:143-148.
29. Pollak M, Richard M: Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 1990;82:1349-1352.
30. Gansler T, Vaghmar N, Olson JJ, Graham SD: Suramin inhibits growth factor binding and proliferation by urothelial carcinoma cell cultures. J Urol 1992;148:910-914.
31. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ewing MW, Linehan WM, Myers CE: Effect of suramin on human prostate cancer cells in vitro. J Urol 1991;145: 393-398.
32. La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC: Suramin-induced polyneuropathy. Neurology 1990;40:954-960.
33. Stiffey-Wilusz J, Boice JA, Ronan J, Fletcher AM, Anderson MS: An ex vivo angiogenesis assay utilizing commercial porcine carotid artery: modification of the rat aortic ring assay. Angiogenesis 2001;4:3-9.
34. Malinda KM, Nomizu M, Chung M, Delgado M, Kuratomi Y, Yamada Y, Kleinman HK, Ponce ML: Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. FASEB J 1999;13:53-62.
35. Nicosia RF, Ottinetti A: Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 1990;26: 119-128.